FluCov: combining data from around the world to understand the impact of COVID-19 on influenza activity
The FluCov Epi-Bulletin provides an overview of the number of positive cases of influenza and SARS-CoV-2 and the percentage of specimens that tested positive from January 2019 onwards in 22 countries across most regions of the world.
National influenza surveillance systems in five European countries: a qualitative comparative framework based on WHO guidance
A new framework can be used to compare influenza surveillance systems qualitatively between countries to allow the identification of structural differences as well as to evaluate adherence to WHO guidance. The framework may be adapted for other infectious
Addressing COVID-19 vaccine hesitancy
This article seeks to summarize the currently available information to address the most common concerns regarding COVID-19 vaccination.
How COVID-19 shaped mental health: from infection to pandemic effects
The Coronavirus Disease 2019 (COVID-19) pandemic has threatened global mental health, both indirectly via disruptive societal changes and directly via neuropsychiatric sequelae after SARS-CoV-2 infection.
Lessons learned from 2 years of influenza vaccinations in the UK and USA during the COVID-19 pandemic as respiratory viruses return
Due to non-pharmaceutical intervention measures the global influenza burden decreased substantially; but with lifting of restrictions a rebound in other respiratory virus pathogens is both plausible and likely.
Infectious diseases and cognition: do we have to worry?
Age-related physiological changes, particularly immune system decline, may contribute to greater vulnerability to infectious diseases in older individuals.
The molecular epidemiology of multiple zoonotic origins of SARS-CoV-2
As 2019 turned into 2020, a coronavirus spilled over from wild animals into people, sparking what has become one of the best documented pandemics to afflict humans.
Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models
The COVID-19 pandemic has been ongoing for more than 2 years now, and new variants such as Omicron are less susceptible to the vaccines developed against earlier lineages of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Orally efficacious lead of the AVG inhibitor series targeting a dynamic interface in the respiratory syncytial virus polymerase
Respiratory syncytial virus (RSV) is a leading cause of lower respiratory infections in infants and the immunocompromised, yet no efficient therapeutic exists. We have identified the AVG class of allosteric inhibitors of RSV RNA synthesis.
Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study
Although human respiratory syncytial virus (RSV) is an important cause of illness and death in older adults, no RSV vaccine has been licensed.
Duration of immune protection of SARS-CoV-2 natural infection against reinfection in Qatar
We investigated duration of protection afforded by natural infection, the effect of viral immune evasion on duration of protection, and protection against severe reinfection, in Qatar, between February 28, 2020 and June 5, 2022.
Research explores possible link between type 1 diabetes and COVID-19
A trio of new studies from the United States and Europe explore a possible link between COVID-19 and new-onset type 1 diabetes (T1D) in children.
